Emerging roles of growth differentiation factor‑15 in brain disorders (Review)

WEI‑WEI JIANG1*, ZI‑ZHEN ZHANG2*, PING‑PING HE3,4*, LI‑PING JIANG1,5, JIN‑ZHI CHEN1, XING‑TING ZHANG1, MI HU1, YANG‑KAI ZHANG1 and XIN‑PING OUYANG1,4*

1Department of Physiology, Institute of Neuroscience Research, Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment, Hengyang Medical College, University of South China; 2Department of Medical Humanities, School of Medicine, Hunan Polytechnic of Environment and Biology; 3Hunan Province Cooperative Innovation Centre for Molecular Target New Drug Study, Nursing School, University of South China; 4Institute of Cardiovascular Research, Key Laboratory for Atherosclerology of Hunan Province, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan 421001; 5Department of Critical Care Medicine, Hunan Taihe Hospital Changsha, Hunan 410004, P.R. China

Received March 5, 2021; Accepted August 6, 2021

DOI: 10.3892/etm.2021.10705

Correspondence to: Dr Xin‑Ping Ouyang, Department of Physiology, Institute of Neuroscience Research, Hengyang Key Laboratory of Neurodegeneration and Cognitive Impairment, Hengyang Medical College, University of South China, 28 Changsheng West Road, Hengyang, Hunan 421001, P.R. China
E‑mail: y1655@163.com

*Contributed equally

Abbreviations: GDF15, growth differentiation factor‑15; GFRAL, GDNF receptor α‑like; AD, Alzheimer's disease; PD, Parkinson's disease; EGR‑1, early growth response‑1; lncRNAs, long non‑coding RNAs; OSCC, oral squamous cell carcinoma; HCC, hepatocellular carcinoma; miRNAs, microRNAs; CCN2, connective tissue growth factor; MSA, methylseleninic acid; ARRB1, β‑arrestin1; LPS, lipopolysaccharide; HRV, human rhinovirus; TGFβRII, TGFβ receptor type II; Aβ, amyloid β; 6‑OHDA, neurotoxin 6‑hydroxydopamine; hUCB‑MSCs, human umbilical cord blood‑derived mesenchymal stem cells

Key words: growth differentiation factor‑15, brain disorders, Alzheimer's disease, cerebral stroke, Parkinson's disease

Abstract. Brain disorders, such as Alzheimer's and Parkinson's disease and cerebral stroke, are an important contributor to mortality and disability worldwide, where their pathogenesis is currently a topic of intense research. The mechanisms underlying the development of brain disorders are complex and vary widely, including aberrant protein aggregation, ischemic cell necrosis and neuronal dysfunction. Previous studies have found that the expression and function of growth differentiation factor‑15 (GDF15) is closely associated with the incidence of brain disorders. GDF15 is a member of the TGFβ superfamily, which is a dimer‑structured stress‑response protein. The expression of GDF15 is regulated by a number of proteins upstream, including p53, early growth response‑1, non‑coding RNAs and hormones. In particular, GDF15 has been reported to serve an important role in regulating angiogenesis, apoptosis, lipid metabolism and inflammation. For example, GDF15 can promote angiogenesis by promoting the proliferation of human umbilical vein endothelial cells, apoptosis of prostate cancer cells and fat metabolism in fasted mice, and GDF15 can decrease the inflammatory response of lipopolysaccharide‑treated mice. The present article reviews the structure and biosynthesis of GDF15, in addition to the possible roles of GDF15 in Alzheimer's disease, cerebral stroke and Parkinson's disease. The purpose of the present review is to summarize the mechanism underlying the role of GDF15 in various brain disorders, which hopes to provide evidence and guide the prevention and treatment of these debilitating conditions.

Contents

1. Introduction
2. Structure and biosynthesis of GDF15
3. Regulation of GDF15 expression
4. Biological functions of GDF15
5. Role of GDF15 in major brain disorders
6. Conclusion and future directions

1. Introduction

Brain disorders, along with malignant tumors and cardiovascular disorders, are among the leading causes of morbidity and mortality worldwide (1). Brain disorders pose a serious socioeconomic burden, where the Global Burden of Disease 2017 data demonstrated that ~324.4 million individuals were affected by brain disorders in Europe, which accounts for
79.1% of all non-communicable diseases in 2017 (1). Although cholinesterase inhibitors and dopamine-like drugs have shown considerable efficacy for the treatment of brain disorders, particularly in patients with degenerative diseases in the central nervous system, side effects and long-term sequelae remain (2). Therefore, a more detailed understanding in the mechanism underlying the progression and pathophysiology of brain disorders is crucial for developing new therapeutic strategies.

Growth differentiation factor-15 (GDF15), which was first identified in the human cDNA library that was enriched for genes associated with macrophage activation using the subtraction cloning approach, is a distant member of the TGFβ superfamily (3). GDF15 is highly expressed in the heart, liver, kidney, intestine, lung, placenta and the prostate gland (4-6). In humans, the physiological concentration of GDF15 lies in the range of 200-1,200 pg/ml, where its levels increase with age (7). It has been reported that GDF15 participates in tissue repair by exerting antiapoptotic and anti-inflammatory effects whilst maintaining vascular endothelial functions (8,9). There is also accumulating evidence that GDF15 is involved in the occurrence and development of cardiovascular diseases, diabetes and cancer (10-12). In 2017, research successively identified glial cell-derived neurotrophic factor receptor α-like (GFRAL) as the receptor of GDF15 (13-16). Discovery of the GDF15/GFRAL signaling pathway provided a potentially novel target for the treatment of obesity and metabolic diseases (16-18). In recent years, accumulating evidence has also indicated that GDF15 is associated with a range of brain disorders, including Alzheimer’s disease (AD), cerebral stroke and Parkinson’s disease (PD) (19-21). Therefore, the aim of the present review is to summarize the regulatory processes and physiological functions of GDF15, with an emphasis on its role in brain disorders.

2. Structure and biosynthesis of GDF15

The GDF15 gene can be mapped onto the chromosome 19p13.1-13.2 genomic locus, which contains two exons and one single intron with an open reading frame of 924 bp (3). Its corresponding mRNA can be translated into a 308-amino acid polypeptide, which is composed of the following three parts: Signal peptide, pro-peptide region and a mature region on the carboxyl terminus (3). The mature domain of 112 amino acids is first separated from the propeptide region of 167 amino acids by a furin-like convertase, which is then cleaved by furin/paired basic amino-acid-cleaving enzyme 4 and MMP-26 (22,23). The mature domain of GDF15 contains a highly conserved pattern of seven cysteine residues, where six of these form intra-chain disulfide bonds, forming a highly stable cysteine structure that is resistant to physical and chemical damage, including enzymatic attacks (24). Unlike other TGFβ families of proteins, the propeptide is not required for proper GDF15 folding (25). Although propeptides may facilitate the detection of improper GDF15 folding, engineered GDF15 that lacks the pro-peptide domain can still be secreted in its proper folded form (26). GDF15 is generally secreted as a dimer that is formed by inter-chain disulphide bonds, which performs complex biological functions through autocrine or paracrine pathways (Fig. 1) (25). In addition, GDF15 can be secreted as an unprocessed pro-peptide, where it can bind to the extracellular matrix (ECM) through its 89 amino acids on the C-terminal domain in a reversible manner in prostate cancer (27). There, GDF15 can be released from the ECM into the circulation by locally acting MMPs or pro-convertases (27).

3. Regulation of GDF15 expression

GDF15 is a type of stress-response protein (28). It was previously reported that GDF15 expression is markedly increased under conditions of inflammation, ischemia, hypoxia and organ damage (29). GDF15 is important for the regulation of angiogenesis, apoptosis, lipid metabolism and inflammation, some of the factors that have been found to regulate GDF15 expression are discussed in this section.

\[ p53 \]

As a tumor suppressor gene, p53 serves a key role in controlling cell proliferation, inhibiting malignant cell proliferation and regulating cell cycle progression (30). p53 was one of the first transcription factors that was identified to be transcriptional regulators of GDF15 expression (31). There are ≥ two p53 binding sites in the GDF15 promoter, one near the transcription start site and another in the region that lie 851 bp upstream of the transcription start site (31), where both binding sites can transactivate the GDF15 promoter (31). It was previously reported that GDF15 expression was robustly upregulated following the overexpression of GFRAL in human lung cancer cell lines (32,33). In addition, the DNA intercalator doxorubicin was found to significantly increase GDF15 expression in p53 wild-type human breast cancer cell lines, but exerted no effects on p53-null cells (34). In vitro, GDF15 expression was found to be markedly increased in human bronchial epithelial cells and human pulmonary vascular endothelial cells upon exposure to hyperoxia, whilst p53 knockdown robustly reduced this induction of GDF15 transcription by hyperoxia (35). Therefore, this suggests that p53 is an important regulator of the production of GDF15. Similarly, C-reactive proteins in human aortic endothelial cells and human maternal expression gene 3 in colon cancer cell lines were both shown to induce GDF15 expression by recruiting the p53 protein (36,37). Different members of the p53 tumor suppressor gene family have been demonstrated to exhibit different binding affinities for GDF15 promoter region contains two p53-type response elements (RE), RE1 and RE2, where most 3’ quarter-sites (areas bound by the p53 tetramer) in RE2 exhibit a higher binding affinity for p53 (38). Therefore, GDF15 is activated by p53 to a greater extent compared with that by other related family members, including p63 and p73 (38).

\[ \text{Early growth response-1 (EGR-1)} \]

EGR-1 is a transcription factor that contains three zinc finger domains and is considered to be an important regulator of GDF15 (39). A number of studies have previously shown that pharmacological agonists, such as troglitazone and non-steroidal anti-inflammatory drugs, can increase EGR-1 expression in human colon cancer cell lines prior to GDF15 induction, supporting the hypothesis that GDF15 is a downstream target of EGR-1 (40-42). Indeed, position -73 to -51 of the GDF15 promoter contains
Figure 1. Synthesis and Secretion of GDF15. (A) GDF15 gene that is located on the chromosome 19p13.1-13.2 genomic locus can produce a mRNA of 1239 BP. And the mRNA is translated into a 308 amino acid polypeptide, which includes signal peptide, pro-peptide region and a mature region. Then the mature domain is separated from the propeptide region by a furin-like convertase. (B) After transcription, translation and processing, GDF15 (yellow circle) is formed into a 62-kDa protein, which is transported into the circulation through vesicles. In addition, the unprocessed GDF15 can also be directly secreted to bind to ECM. After hydrolysis by metalloenzymes or pro-convertases, GDF15 enters the circulation from ECM. GDF15, growth differentiation factor-15; ECM, extracellular matrix.
EGR-1-binding sites (43). Furthermore, DNA methylation at the -53 site of the GDF15 promoter site blocks the binding of EGR-1, which subsequently inhibits GDF15 induction in vitro (43). By contrast, GDF15 transcription by EGR-1 can be restored following incubation with 5-aza-2-deoxycytidine (a demethylating reagent) (43). Accordingly, in HT29 colon carcinoma cells, activity of the GDF15 promoter and GDF15 expression are markedly increased by the ectopic expression of EGR-1 in a dose-dependent manner, whereas EGR-1 knockdown using small interfering (si)RNAs was shown to significantly decrease silibinin-induced GDF15 expression (44). These observations suggest that EGR-1 is a direct transcriptional regulator of GDF15.

**Long non-coding RNAs (lncRNAs) and microRNAs (miRNAs/miRs).** LncRNAs represents a class of RNAs that cannot be translated into proteins and are typically >200 nucleotides in length (45). It has been reported extensively that lncRNAs can serve key roles in the regulation of gene expression. Kong et al (46) previously revealed that LINC0113 overexpression decreased the mRNA and protein expression levels of GDF15 in oral squamous cell carcinoma (OSCC) cell lines, whilst treatment with the exogenous recombinant human GDF15 protein was able to restore the migratory and invasive abilities of OSCC cells that was previously weakened by LINC0113. In addition, a significant positive correlation was identified between lncRNA plasmacytoma variant translocation 1 (PVT1) expression and GDF15 expression in hepatocellular carcinoma (HCC) tissues (47). GDF15 knockdown using siRNAs significantly suppressed the proliferation of HCC cells caused by lncRNA PVT1 overexpression, suggesting that lncRNA PVT1 may be an important upstream regulator of GDF15 expression in HCC cells (47). Another study also revealed that CCAAT enhancer-binding protein β (CEBPB) can bind to the promoter of GDF15 to facilitate GDF15 gene expression in ovarian cancer cell lines (48). In addition, GDF15 expression was previously found to be negatively associated with that of the lncRNA growth arrest-specific 5 (GASS) in ovarian cancer tissues (48). Mechanistically, lncRNA GASS was shown to competitively bind to CEBPB to inhibit the promoting effect of CEBBP on GDF15 transcription (48). It is expected that additional lncRNAs involved in the regulation of GDF15 expression will be discovered by future studies.

Similar to lncRNAs, miRNAs are also an important component of gene transcription regulators, which functions by pairing with the 3’-untranslated region of target mRNAs (49). Both miR-873-5p and miR-1233-3p have been shown to exert suppressive effects on GDF15 expression in melanoma cell lines (50). However, single-nucleotide polymorphism in miRNA, rs1054564, was located in the GDF15’UTR complementary to the hsa-miR-1233-3p seed region, and the presence of this C-allele was discovered to weaken the binding of hsa-miR-1233-3p to GDF15, thereby enhancing the expression of the GDF15 protein (50). miR-3189 is a primate-specific miRNA that is embedded within the introns of GDF15 (51). Increased miR-3189 expression results in elevated GDF15 expression by down-regulating p53 in colorectal cancer cell lines (51). In addition, overexpression of miR-3189 in HCT116-p53+ colorectal cancer cells was shown to upregulate the expression of a subset of p53 targets, including GDF15 and growth arrest and DNA-damage-inducible 45α (51).

**Hormones and hormone derivatives.** Hormones and hormone derivatives have also been demonstrated to lie upstream of GDF15 (52). Primary adrenal insufficiency is accompanied by an increase in GDF15 expression, where glucocorticoid replacement therapy was shown to effectively reduce this concentration of GDF15 in a dose-dependent manner (53). In brown adipose tissues, noradrenergic cAMP-mediated thermogenic activation was found to increase GDF15 gene expression and subsequent release (54). In addition, metformin was reported to increase GDF15 levels, but it had no effect on GFRAL receptor-deficient mice (52). Zhao et al (55) previously found that thyroid hormone levels were independently associated with GDF15 expression, such that T3 treatment promoted GDF15 expression in brown adipose tissues of C57BL/6 mice. Furthermore, previous in vivo and vitro experiments demonstrated that testosterone and estradiol treatment reduced GDF15 secretion through androgen receptor/estrogen receptor-mediated signaling pathways (56).

4. Biological functions of GDF15

**Angiogenesis.** Accumulating evidence has suggested that GDF15 is a potential stimulator of angiogenesis (Table I). After being secreted by senescent endothelial colony-forming cells generated from adult human blood in a paracrine manner, GDF15 can promote proliferation, migration and NO production in non-senescent endothelial colony-forming cells generated from adult human blood (57). During this process, a number of signaling pathways are activated by GDF15 in an oxidative stress-independent manner, including AKT, ERK1/2 and Smad2 (57). This improved the function of vascular progenitor cells, which may serve therapeutic effects on the damaged vascular system (57). Similarly, GDF15 can also enhance the expression of cyclins D1 and E in HUVECs through the PI3K/AKT, JNK and ERK signaling pathways to promote the proliferation of endothelial cells (58). GDF15 is also involved in the mechanism underlying ischemia/reperfusion injury. During the process of cardiac ischemia, GDF15 was shown to stimulate the angiogenesis of hypoxic HUVECs by inhibiting p53 signaling whilst upregulating hypoxia-inducible factor 1α expression (59). Furthermore, since the repair of large bone defects remains to be a major medical challenge, GDF15 was shown to represent a potentially effective solution. Wang et al (60) found that GDF15 can promote the formation of functional blood vessels at the site of artificially-induced angiogenesis, which significantly improved the healing of critical-sized calvarial defects. Neovascularization is one of the major characteristics in cancer (61). Following chemotherapy, the expression of GDF15 was found to be markedly upregulated in HCC (62). GDF15 can induce Src and then activate AKT, MAPK and NF-xB downstream in HCC, which promotes the proliferation, migration and tube formation of surrounding endothelial cells in vitro (62). By contrast, thalidomide, an agent with known anti-angiogenic activities, can significantly attenuate and reverse these effects aforementioned (62). In addition, it was found that GDF15 interacted with connective tissue growth factor (CCN)-2, to inhibit
CCN2-mediated focal adhesion kinase activation, which in turn decreased avβ3 integrin clustering in HUVECs, to exert antagonistic effects on angiogenesis (63). This phenomenon is conducive to understanding the role of GDF15 under various disease conditions further.

**Cell apoptosis.** Apoptosis is a process in which cell death occurs in an orderly manner and is crucial for the maintenance of internal homeostasis (64). Owing to its reported function as a stress-response protein, GDF15 has been reported to regulate apoptosis (65). GDF15 is a downstream target of methylseleninic acid (MSA), where GDF15 knockdown significantly inhibited the apoptosis of prostate cancer cells mediated by MSA (66,67). By contrast, GDF15 overexpression made prostate cancer cells flatter and more spread out and induced caspase-dependent apoptosis (66,67). GDF-15 was inducible in human macrophages by oxidized low density lipoprotein and its mediators in vitro, and GDF15 immunoreactivity was colocalized with apoptosis markers such as PARP, caspase-3 or apoptosis-inducing factor immunoreactivity, suggesting that GDF15 may modulate apoptosis process in activated macrophages (68). In addition, A549 lung adenocarcinoma cell apoptosis was also induced by GDF15 overexpression through promoting caspase-9 and caspase-3 expression and inhibition of ERK1/2 and p38 MAPK phosphorylation, which was mediated in a TGFβ receptor type II (TGFβRII)-dependent manner (69). Conversely, GDF15 can exert a protective effect against the apoptosis of HUVECs induced by high glucose concentrations (70). Mechanistically, this effect may be caused by GDF15 maintaining the activity of PI3K/Akt/eNOS pathway and attenuating NF-κB/JNK pathway (70). In addition, under conditions of hypoxia and laminar shear stress, GDF15 expression in the pulmonary microvascular endothelial cells of patients with pulmonary arterial hypertension was found to be significantly higher compared with that in normal lung tissues, where the extent

### Table I. Biological functions of GDF15.

| Actions                  | Experimental models                  | Mechanisms                                                                 | (Refs.) |
|-------------------------|--------------------------------------|-----------------------------------------------------------------------------|---------|
| **Angiogenesis**        |                                      |                                                                             |         |
| Pro-angiogenesis        | Endothelial colony forming cells     | ↑NO, ↑AKT, ERK1/2 and SMAD2                                                 | (57)    |
|                         | generated from adult human blood     |                                                                             |         |
| HUVEC                   |                                      | ↑Cyclin D1 and E, ↑retinoblastoma phosphorylation and E2F-1 nuclear translocation | (58)    |
| HUVEC                   |                                      | ↓p53, hypoxia-induced factor-1α                                              | (59)    |
| Hepatocellular carcinoma|                                      | ↑Src and AKT, MAPK and NF-kB downstream                                      | (62)    |
| **Anti-angiogenesis**   | HUVEC                                | ↓Connective tissue growth factor 2/focal adhesion kinase                    | (63)    |
| **Apoptosis**           |                                      |                                                                             |         |
| Pro-apoptosis           | Prostate cancer cells                | ↑Methylseleninic acid, ↑caspase-dependent apoptosis                          | (66,67) |
|                         | Activated macrophages                | ↑ PARP, caspase-3 or AIF                                                     | (68)    |
|                         | A459 cells                           | ↑caspase-9 and caspase-3; ↓ERK1/2 and p38 MAPK phosphorylation               | (69)    |
| Anti-apoptosis          | HUVEC                                | ↑PI3K/AKT/endothelial nitric oxide synthase; ↓NF-kB/JNK                      | (70)    |
|                         | Patients with pulmonary hypertension | ↑AKT                                                                        | (71)    |
| Lipid metabolism        | Transgenic GDF15 mice                | ↑Key thermogenic and lipolytic genes                                         | (73)    |
|                         | Mice fed with high-fat diet          | ↑Glial cell-derived neurotrophic factor receptor α-like                      | (74)    |
|                         | Patients with non-alcoholic steatohepatitis | ↑β-arrestin1; ↑β-oxidation genes; ↓fatty acids                               | (75)    |
|                         | Fasted mice                          | ↑Fatty acid β-oxidation and ketogenesis                                      | (76)    |
| Inflammation            | Mice treated with lipopolysaccharide | ↓Monocyte chemoattractant protein-1, TNF-α, transforming growth factor-β-activated kinase 1 phosphorylation and NF-kB | (79,81) |
|                         | Mice                                 | ↑Triglyceride metabolism                                                    | (77)    |
| Pro-inflammatory        | Human GDF15 transgenic mice          | ↓IFN-λ2/3 mRNA                                                              | (78)    |
|                         | Human transgenic mice tracheal        | ↓IFN-λ1/IL-29                                                               | (78)    |

↑, enhancement or promotion; ↓, reduction or inhibition; GDF-15, growth differentiation factor-15; HUVECs, human umbilical cord vascular endothelial cells; IFN, interferon.
of cell apoptosis was reduced by GDF15 overexpression in an AKT-dependent manner (71).

**Lipid metabolism.** GDF15 can serve as a potential lipid metabolism regulator (72). GDF15 overexpression conferred higher resistance to diet- and genetic-induced obesity in transgenic GDF15 mice compared with that in wild-type mice by increasing lipid oxidation whilst promoting the expression of thermogenic genes and adipose tissue metabolism (73). Following treatment with the GDF15 antibody, the weight, obesity and the degree of liver lipid deposition of mice fed on a high-fat diet were markedly higher compared with those in the control group (74). Therefore, GDF15 may be a potential target for the treatment of fatty liver disease. Zhang et al (75) revealed that β-arrestin 1 (ARRB1) deficiency in patients with non-alcoholic steatohepatitis was accompanied with increased free fatty acid levels and decreased β-oxidation gene expression in a GDF15-dependent manner in liver. In addition, ARRB1 was found to interact with GDF15 to promote the translocation of the GDF15 precursor to the Golgi body for cleavage and maturation (75). During fasting, the inositol-requiring enzyme 1α/X-box binding protein axis can increase the expression of GDF15 by binding to its promoter to promote fatty acid oxidation and ketone production in the liver (76). However, GDF15 knockout can significantly suppress β-oxidation and ketogenesis in mice with streptozocin-induced type I diabetes or in mice subjected to fasting (76).

**Inflammatory response.** In addition to the aforementioned functions, GDF15 can also exert anti-inflammatory and proinflammatory properties (77,78). GDF15 can inhibit the inflammatory response induced by lipopolysaccharide (LPS) (79). A previous study demonstrated that GDF15-knockout mice displayed worsened characteristics following the induction of LPS-induced renal and cardiac injury, whilst GDF15 overexpression conferred opposite effects (80). GDF15 can inhibit the activation of the NF-κB pathway to reduce the production of proinflammatory factors, including monocyte chemoattractant protein-1 and TNF-α (81). In this effect prevents LPS-induced liver injury in mice by blocking the phosphorylation of TGFβ-activated kinase 1 (81). Luan et al (77) previously reported that GDF15 improved cardiac and hepatic tolerance to inflammation in mice by regulating triglyceride metabolism. GDF15 was also found to regulate the response to human rhinovirus (HRV) infection and virus-induced lung inflammation (78). In human GDF15 transgenic mice, the overexpression of GDF15 resulted in enhanced inflammatory responses to HRV and decreased IFN-λ/3 mRNA expression (78). In addition, the IFN-λ1/IL-29 protein, which has antiviral activity, was found to be inhibited by GDF15 in tracheal epithelial cells from human GDF15 transgenic mice, which promoted HRV replication and the subsequent inflammatory response (78).

### 5. Role of GDF15 in major brain disorders

**AD.** AD is a progressive neurodegenerative disease that mainly manifests with clinical symptoms of cognitive and behavioral impairment (82). The pathogenesis of AD is complex and may involves amyloid β (Aβ) accumulation, tau protein toxicity, synaptic damage, mitochondrial dysfunction and oxidative stress (83). GDF15 expression can be detected in the adult rat central and peripheral nervous systems, where it is mainly secreted into the cerebrospinal fluid (84,85). It has been demonstrated that GDF15 is closely associated with cognitive impairment, which is a major characteristic of AD (86). It was also previously shown that cognitive impairments due to dementia and AD were associated with higher GDF15 levels, particularly in the presence of cerebrovascular disease (87). By contrast, GDF15-deficient mice were shown to exhibit superior fear-associated memory and sensorimotor gating, which is conducive to cognition (88). Decreased numbers of white matter and grey matter nerve fibers, coupled with the increased volume of atrophy, may be important pathophysiological features of AD (89). Jiang et al (90,91) revealed that higher GDF15 levels were negatively correlated with gray matter volume and white matter integrity. In addition, GDF15 expression likely exhibits a close association with learning and memory impairments, where the hippocampus is the region that is typically worst affected by AD (86,92). GDF15-knockout mice were shown to display a progressive loss of motor neurons coupled with the decreased proliferation and migration of adult hippocampal progenitor cells (93,94). This appears to be a result of the absence of epidermal growth factor receptor signaling stimulation, which is normally promoted by GDF15 in a CXC chemokine receptor 4-dependent manner (93,94). Kim et al (95) reported that human recombinant GDF15 can enhance the proliferation and synaptic activity of mouse hippocampal neural stem cells both in vitro and in vivo, whereas GDF15 knockdown can reduce the proliferation of hippocampal neural stem cells in vitro. Within the neural network, the synapse forms a key component in mediating signal transmission between neurons, which underlies the mechanism of the generation and retention of memories (96). It was previously reported that GDF15 promoted synaptic glutamate release and increased the miniature excitatory post-synaptic current frequency in the medial prefrontal cortex of mice (97). The potential mechanism was mediated through activation of TGFβRII-mediated ERK1/2 signaling to promote Ca$_2^+$, Ca$_3^+$ and Ca$_4^+$ subunit expression, which increases T-type calcium channel activity (97). This suggests that GDF15 deficiency may impact synaptic function and accelerate AD progression (97). The production and accumulation of Aβ is one of the main mechanisms underlying AD development (98). TGFβRII is mainly expressed in the microglia and neurons, where it participates in GDF15-associated signaling pathways including Akt/mTOR pathway. GDF15 as a soluble paracrine factor can act on microglial cells to increase the expression level of TGFβRII during AD (12). In addition, GDF15 can enhance the activity of insulin-degrading enzyme which, together with TGFβRII, can promote Aβ protein clearance (12). Decreased expression levels of TGFβRII were found in human and mouse models of AD, which may be the underlying cause of the increased Aβ accumulation and neurodegeneration (Fig. 2) (99,100). In summary, GDF15 appears to be involved in AD not only by promoting hippocampal neurogenesis and synaptic activity, but also by enhancing the clearance of the Aβ protein. Therefore, GDF15 may represent an attractive therapeutic target for AD.
Cerebral stroke. Cerebral stroke is an acute cerebrovascular disease, the pathogenesis of which is characterized by inadequate blood flow to the brain due to the rupture or occlusion of cerebrovascular vessels, thereby causing brain damage (101). Stroke can be divided into two categories, namely ischemic and hemorrhagic stroke, where American Stroke Association data in 2018 indicated that ischemic stroke accounted for 87% of all cases (102). Since GDF15 levels were found to be elevated after tissue injury, ischemia or hypoxia, it was hypothesized that there may be an association between GDF15 and stroke. Xiang et al (103) demonstrated that the genotype and allele frequencies of the GDF15 rs1804826G/T polymorphism were associated with the risk of cerebral stroke within the Chinese population. In a prospective, nested, case-controlled study of 27,628 initially healthy female individuals, Brown et al (104) revealed that the GDF15 concentration in patients with cardiovascular events, including stroke, was higher compared with that in individuals without cardiovascular events. In addition, a concentration higher than the 90th percentile (>856 pg/ml) was associated with a 2.7-fold increase in the risk of developing cardiovascular events (104). Previous studies reported that GDF15 levels may serve as a prognostic marker in patients with a history of stroke (105,106). Several lines of evidence also revealed that the level of GDF15 was found to be positively associated with the severity of ischemic stroke, such that GDF15 can be used as a biomarker for predicting an unfavorable outcome 90 days after the stroke event (107,108). Plasma GDF15 concentration on admission has been reported to serve as an independent prognostic biomarker of mortality in patients with ischemic stroke following acute revascularization therapy (17). A previous study also investigated the relationship between GDF15 and in 254 patients with hypertension who suffered from stroke for the first, which found that GDF15 can be used as an independent predictor of stroke in individuals without any prior history of stroke (109). In addition, it was reported that GDF15 mRNA expression was markedly upregulated in the hippocampus and parietal cortex of mice at 3 and 24 h after middle cerebral artery occlusion (110). This suggests that GDF15 can participate in the regulation of post-lesion responses, further supporting the notion that GDF15 participates in the occurrence and development of cerebral stroke (110).

PD. The main property of PD is the degeneration and loss of dopaminergic neurons in the substantia nigra and nigrostriatal pathway, which is caused by the formation of Lewy bodies as a result of aberrant α-synuclein deposition (111). PD is characterized by symptoms of dyskinesia, including tremor, stiffness, slow motion and unstable posture (111). PD also has a complex and multifactorial pathological process, which typically involves the aggregation of α-synuclein, oxidative stress, mitochondrial dysfunction, iron deposition and neuronal apoptosis (112). Maetzler et al (113) previously revealed that GDF15 exhibited a positive correlation with the age of PD symptom onset, Hoehn and Yahr scale score and expression of the neurodegenerative marker Tau. GDF15 was also identified to be an independent risk factor for Unified Parkinson’s Disease Rating Scale-III score through multiple linear regression analysis, where subsequent receiver operating characteristic curve analysis revealed that GDF15 exhibited a sensitivity of 71.15% and a specificity of 87.50% for the detection of PD (114,115). However, since GDF15 levels exhibit substantial overlap between patients with PD and healthy individuals, this marker alone may not be sufficient as a diagnostic tool. However, these aforementioned findings indicate collectively that GDF15 expression is closely associated with PD.

The neurotoxin 6-hydroxydopamine (6-OHDA) can be taken up preferentially by dopaminergic and noradrenergic transporters, leading to the degeneration of catecholaminergic neurons (116). Strelau et al (84) demonstrated that unilateral injections of GDF15 into the medial forebrain bundle immediately above the substantia nigra prior to 6-OHDA
administration were able to confer protection against complete lesion formation induced by 6-OHDA, which prevented the loss of the dopaminergic neurons. Consistently, Machado et al. (117,118) further demonstrated that endogenous GDF15 may promote the survival of dopaminergic neurons by regulating the inflammatory response after 6-OHDA-induced brain injury. GDF15 released by astrocytes exerted a protective effect on vulnerable nigral neurons during PD and on induced pluripotent stem cell-derived dopaminergic neurons subjected to 1-methyl-4-phenylpyridinium toxicity, which may explain the selective degeneration or protection of dopaminergic neurons in PD because GDF15 is expressed 230-fold higher in the neighboring ventral tegmental area astrocytes than the substantia nigra pars compacta (20,119). Mitochondrial dysfunction is another possible mechanism that has been proposed to serve a role in PD (112). The HT22 hippocampal cell line is considered to be a suitable model for studying PD. GDF15 overexpression was shown to reverse the effects of oxygen consumption, cell viability and mitochondrial membrane potential caused by oligomycin in HT22 cells, where further study revealed that GDF15 may regulate mitochondrial membrane potential and oxygen consumption through the PI3K/AKT signaling pathway (120). Furthermore, GDF15 was reported to be a more sensitive measure for diagnosing mitochondrial dysfunction compared with that of lactate stress test in Japanese patients with PD (121). Collectively, these findings suggest that GDF15 may promote the survival of dopaminergic neurons and exerts a protective effect by preserving normal mitochondrial function.

6. Conclusion and future directions

GDF15 is widely expressed in brain tissues and has been found to be involved in the pathophysiological processes underlying a number of brain disorders, particularly in AD, cerebral stroke and PD. Although progress has been made over the past decade, several unresolved problems remain. The specific signaling pathways mediated by GDF15 in AD have not been fully elucidated. In addition, the reference range and sensitivity of GDF15 as a biomarker for the prognosis and risk stratification of related diseases have yet to be determined. Furthermore, it remains unknown if there are other GDF15 receptors involved in mediating the pathophysiological processes of brain disorders in addition to the GFRAL receptor. Whether the plasma concentration of GDF15 can be artificially regulated to treat brain disorders is also a question that require further study. Therefore, addressing these questions aforementioned may provide further clues for the prevention and treatment of these brain disorders.

Acknowledgements

Not applicable.

Funding

The authors acknowledge the financial supports from the Natural Science Foundation of Hunan Province, (grant nos. 2019JJ40249 and 2018JJ3455), Outstanding Young Aid Program for Education Department of Human Province (grant no. 18B274), the Major Project of Social Science Achievement Review Committee in Hunan Province (grant no. XSP20ZD013), Key Project of Hunan Provincial Department of Education (grant no. 20A427).

Availability of data and materials

Not applicable.

Authors' contributions

WWJ, ZZZ, PPH, XPO contributed to data gathering, manuscript drafting, critical revision of the manuscript. LPJ, JZC, XTZ, MH and YKZ revised the manuscript. All authors read and approved the final manuscript. Data authentication is not applicable.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Raggi A and Leonardi M: Burden of brain disorders in Europe in 2017 and comparison with other non-communicable disease groups. J Neurol Neurosurg Psychiatry 91: 104-105, 2020.
2. Bautista-Aguliera OM, Ismaili L, Iriepa I, Diez-Iriepa I, Chabchoub F, Marco-Contelles J and Pérez M: Tacrines as therapeutic agents for alzheimer’s disease. V. recent developments. Chem Rec 21: 162-174, 2021.
3. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, et al: MIC-1: a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci USA 94: 11514-11519, 1997.
4. Yokoyama-Kobayashi M, Saeki M, Sekine S and Kato S: Human cDNA encoding a novel TGF-beta superfamily protein highly expressed in placenta. J Biochem 122: 622-626, 1997.
5. Bottner M, Laffa M, Schechinger B, Rappold G, Unsicker K and Suter-Crazzolara C: Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). Gene 237: 105-111, 1999.
6. Koopmann J, Buckhaults P, Brown DA, Zahrurak ML, Sato N, Fukushima N, Sokoll LJ, Chan DW, Yeo CJ, Huang RB, et al: Serum macrophage inhibitory cytokine-1 is a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: 2386-2392, 2004.
7. Wiklund FE, Bennet AM, Magnusson PK, Eriksson UK, Lindmark F, Wu L, Yaghoubifam N, Marquis CP, Stattin P, Pedersen NL, et al: Macrophage inhibitory cytokine-1 (MIC-1/GDF15): A new marker of all-cause mortality. Aging Cell 9: 1057-1064, 2010.
8. Conte M, Martucci C, Chiariello A, Franceschi C and Salvioni S: Mitochondria, immunosenescence and inflammaging: A role for mitokines? Semin Immunopathol 42: 607-617, 2020.
9. Rochette L, Zeller M, Cottin Y and Vergely C: Insights into mechanisms of GDF15 and receptor GFRAL: Therapeutic targets. Trends Endocrinol Metab 31: 939-951, 2020.
10. Kang YE, Kim JM, Lim MA, Lee SE, Yi S, Kim JT, Oh C, Liu L, Jin Y, Jung SN, et al: Growth differentiation factor 15 is a cancer cell-induced mitokine that primes thyroid cancer cells for invasiveness. Thyroid 31: 772-786, 2021.
11. Nakayasu ES, Syed F, Tersey SA, Gritsenko MA, Mitchell HD, Chan CY, Dirice E, Turatsinze JV, Cui Y, Kulkarni RN, et al: "Comprehensive proteomics analysis of stressed human islets identifies a target for type 1 diabetes intervention. Cell Metab 31: 363-374.e6, 2020.

12. Wang Y, Zhen C, Wang R and Wang G: "Growth-differentiation factor-15 predicts adverse cardiac events in patients with acute coronary syndrome: A meta-analysis. Am J Emerg Med 37: 1266‑1272, 2020.

13. Yang L, Chang CC, Sun Z, Madsen D, Zhu H, Padkar SB, Wu X, Huang T, Hultman K, Paulsen SJ, et al: "GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat Med 23: 1158‑1166, 2017.

14. Bullician SE, Lin-Schmidt X, Chin CN, Chavez JA, Furchang AA, Beck JM, Guo Z, Ji X, Vranic M, Cash-Mason TD, et al: "GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med 23: 1150‑1157, 2017.

15. Hsu JY, Crawley S, Chen M, Ayupova DA, Lindhout DA, Higbee J, Kureishi A, Joo W, Gao Z, Fu D, et al: "Non‑homoeostatic body weight regulation through a brainstem‑restricted receptor for GDF15. Nature 550: 255‑259, 2017.

16. Emmerson PJ, Wang F, Du Y, Liu Q, Pickard RT, Gonciarz MD, Coskun T, Hamang MJ, Bauskin AR, Brown DA, Junankar S, Rasiah KK, Eggleton S, Couture F, Sabbagh R, Kwiatkowska A, Desjardins R, Guay SP, Borner T, Shaulson ED, Ghidewon MY, Barnett AB, Horn CC, Doyle RP, Grill HJ, Hayes MR and De Jonghe BC: "GDF15 induces anorexia through Nausea and Eumesis. Cell Metab 28: 353‑368, 2018.

17. Yang H, Filipovic Z, Brown D, Breit SN and Vassilev LT: "Role in determining prostate cancer outcome. Cancer Res 65: 1782‑1792, 2005.

18. Zeng X, Yuan J, Zhang N, Zheng Y, Liu J and Yang M: "GDF15 signaling and suppresses hepatocarcinogenesis. Biochem Biophys Res Commun 501: 1782‑1792, 2021.

19. Bauskin AR, Zhang HP, Fairlie WD, He XY, Russell PK, Moore AG, Brown DA, Stanley KK and Breit SN: "The TGF‑beta superfamily member, acts as a quality control determinant for correctly folded MIC‑1. EMBO J 19: 2212‑2220, 2000.

20. Baik SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: "Identification of NAG‑1, a transforming growth factor‑beta superfamily member, by troglitazone requires the early growth response gene EGR‑1. J Biol Chem 279: 6883‑6892, 2004.

21. Baik SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: "Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR‑1, which results in the upregulation of NAG‑1, an antitumorigenic protein. Mol Pharmacol 67: 356‑364, 2000.

22. Chintchalapalli S, Papineni S, Baik SJ, Liu S and Safe S: "1,1‑Bis(3‑indolyl)‑1‑(p‑substitutedphenyl)ethanes are peroxisome proliferator‑activated receptor gamma agonists but decrease HCT‑116 colon cancer cell survival through receptor‑independent activation of early growth response‑1 and nonsteroidal anti‑inflammatory drug‑activated gene‑1. Mol Pharmacol 68: 1782‑1792, 2005.

23. Kadowaki M, Yoshihata K, Kamitani H, Watanabe T, Wade PA and Eling TE: "Microarray‑based detection of genes regulated by TGF‑beta is a downstream mediator of the growth arrest and toxicity. Toxicol In Vitro 29: 1369‑1376, 2015.

24. Kim Y, Noren Houten N and Evans MK: "CRP stimulates GDF15 expression in endothelial cells through p35. Mediators Inflamm 2018: 8278039, 2018.

25. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Angel PJ, Zhao JW and Zlotnik A: "Activation of p35 by MEG3 non‑coding RNA. J Biol Chem 282: 24731‑24742, 2007.

26. Osada M, Park HL, Park MJ, Liu JW, Wu G, Trink B and Sidransky D: "A p35‑type response element in the GDF15 promoter confers high specificity for p35 activation. Biochem Biophys Res Commun 413: 918‑923, 2012.

27. Pagel J and Deindl E: "Disease progression mediated byegr‑associated signaling in response to oxidative stress. Int J Mol Sci 13: 1304‑1311, 2012.

28. Baek SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: "Expression of NAG‑1, a transforming growth factor‑beta superfamily member, by troglitazone requires the early growth response gene EGR‑1. J Biol Chem 279: 6863‑6892, 2004.

29. Baek SJ, Kim JS, Moore SH, Lee SH, Martinez J and Eling TE: "Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR‑1, which results in the upregulation of NAG‑1, an antitumorigenic protein. Mol Pharmacol 67: 356‑364, 2000.

30. Cash‑Mason TD, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Bouchard L and Day R: "PACE4 undergoes an oncogenic alteration in human umbilical cord blood‑derived mesenchymal stem cells on microarray‑based detection of genes regulated by TGF‑beta is a downstream mediator of the growth arrest and toxicity. Toxicol In Vitro 29: 1369‑1376, 2015.

31. Baik SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: "Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR‑1, which results in the upregulation of NAG‑1, an antitumorigenic protein. Mol Pharmacol 67: 356‑364, 2000.

32. Chintchalapalli S, Papineni S, Baik SJ, Liu S and Safe S: "1,1‑Bis(3‑indolyl)‑1‑(p‑substitutedphenyl)ethanes are peroxisome proliferator‑activated receptor gamma agonists but decrease HCT‑116 colon cancer cell survival through receptor‑independent activation of early growth response‑1 and nonsteroidal anti‑inflammatory drug‑activated gene‑1. Mol Pharmacol 68: 1782‑1792, 2005.

33. Kadowaki M, Yoshihata K, Kamitani H, Watanabe T, Wade PA and Eling TE: "Microarray‑based detection of genes regulated by TGF‑beta is a downstream mediator of the growth arrest and toxicity. Toxicol In Vitro 29: 1369‑1376, 2015.

34. Kim Y, Noren Houten N and Evans MK: "CRP stimulates GDF15 expression in endothelial cells through p35. Mediators Inflamm 2018: 8278039, 2018.

35. Zhou Y, Zhong Y, Wang Y, Zhang X, Batista DL, Gejman R, Angel PJ, Zhao JW and Zlotnik A: "Activation of p35 by MEG3 non‑coding RNA. J Biol Chem 282: 24731‑24742, 2007.

36. Osada M, Park HL, Park MJ, Liu JW, Wu G, Trink B and Sidransky D: "A p35‑type response element in the GDF15 promoter confers high specificity for p35 activation. Biochem Biophys Res Commun 413: 918‑923, 2012.

37. Pagel J and Deindl E: "Disease progression mediated byegr‑associated signaling in response to oxidative stress. Int J Mol Sci 13: 1304‑1311, 2012.

38. Baek SJ, Kim JS, Nixon JB, DiAugustine RP and Eling TE: "Expression of NAG‑1, a transforming growth factor‑beta superfamily member, by troglitazone requires the early growth response gene EGR‑1. J Biol Chem 279: 6863‑6892, 2004.

39. Baek SJ, Kim JS, Moore SH, Lee SH, Martinez J and Eling TE: "Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR‑1, which results in the upregulation of NAG‑1, an antitumorigenic protein. Mol Pharmacol 67: 356‑364, 2000.

40. Chintchalapalli S, Papineni S, Baik SJ, Liu S and Safe S: "1,1‑Bis(3‑indolyl)‑1‑(p‑substitutedphenyl)ethanes are peroxisome proliferator‑activated receptor gamma agonists but decrease HCT‑116 colon cancer cell survival through receptor‑independent activation of early growth response‑1 and nonsteroidal anti‑inflammatory drug‑activated gene‑1. Mol Pharmacol 68: 1782‑1792, 2005.

41. Kadowaki M, Yoshihata K, Kamitani H, Watanabe T, Wade PA and Eling TE: "Microarray‑based detection of genes regulated by TGF‑beta is a downstream mediator of the growth arrest and toxicity. Toxicol In Vitro 29: 1369‑1376, 2015.

42. Kim Y, Noren Houten N and Evans MK: "CRP stimulates GDF15 expression in endothelial cells through p35. Mediators Inflamm 2018: 8278039, 2018.
Tavosi G and Ghahremani MH: GDF15 induced apoptosis and macrophages in vitro and in arteriosclerotic lesions. Cell Tissue Kine-1 (GDF-15/MIC-1) in oxLDL-induced apoptosis of human endothelial cells. Cancer Res 63: 5034‑5040, 2003.

Schlittenhardt D, Schober A, Strelau J, Bonaterra GA, Barth M, Schilling L, Fairlie WD, Britz SN, and Eickelberg O: Overproduction of growth differentiation factor 15 suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2). J Cell Biochem 114: 108792, 2019.

Jin YJ, Lee JH, Kim YM, Oh GT and Lee H: Macrophage inhibitory cytokine‑1 stimulates proliferation of human umbilical vein endothelial cells by up‑regulating cyclins D1 and E through the p53/HIF‑1 signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 39: 4017‑4022, 2012.

Song H, Yin D and Liu Z: GDF‑15 promotes angiogenesis through modulating p53/HIF‑1α signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 39: 4017‑4022, 2012.

Wang S, Li M, Zhang W, Hua H, Wang N, Zhao J, Ge J, Jiang X, Zhang Z, Ye D and Yang C: Growth differentiation factor 15 promotes blood vessel growth by stimulating cell cycle progression in repair of critical‑sized calvarial defect. Sci Rep 7: 9027, 2017.

Lugano R, Ramachandran M and Dimberg A: Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77: 1745‑1770, 2020.

Jin YJ, Lee JH, Kim YM, Oh GT and Lee H: Macrophage inhibitory cytokine‑1 stimulates proliferation of human umbilical vein endothelial cells by up‑regulating cyclins D1 and E through the p53/HIF‑1 signaling pathway in hypoxic human umbilical vein endothelial cells. Mol Biol Rep 39: 4017‑4022, 2012.

Wang S, Li M, Zhang W, Hua H, Wang N, Zhao J, Ge J, Jiang X, Zhang Z, Ye D and Yang C: Growth differentiation factor 15 promotes blood vessel growth by stimulating cell cycle progression in repair of critical‑sized calvarial defect. Sci Rep 7: 9027, 2017.

Lugano R, Ramachandran M and Dimberg A: Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77: 1745‑1770, 2020.

Wang S, Li M, Zhang W, Hua H, Wang N, Zhao J, Ge J, Jiang X, Zhang Z, Ye D and Yang C: Growth differentiation factor 15 promotes blood vessel growth by stimulating cell cycle progression in repair of critical‑sized calvarial defect. Sci Rep 7: 9027, 2017.

Wang S, Li M, Zhang W, Hua H, Wang N, Zhao J, Ge J, Jiang X, Zhang Z, Ye D and Yang C: Growth differentiation factor 15 promotes blood vessel growth by stimulating cell cycle progression in repair of critical‑sized calvarial defect. Sci Rep 7: 9027, 2017.
The relationship of growth differentiation factor 15 is associated with unfavorable clinical outcomes. Yin J, Zhu Z, Guo D, Wang A, Zeng N, Zheng X, Peng Y, Worthmann H, Kempf T, Widera C, Tryc AB, Goldbecker A, et al. Lancet 359: 2159-2163, 2002.

Growth differentiation factor-15 serum levels and risk of ischemic stroke. Brown DA, Crawford JD, Thalamathu A, Smith E, Breit SN, Liu T, Brodaty H, et al. PLoS One 10: e0123399, 2015.

Plasma growth differentiation factor 15 predicts first-ever stroke in hypertensive patients. Wang X, Zhu L, Wu Y, Sun K, Su M, Yu L, Chen J, Li W, Yang J, Yuan Z and Hui R. PLoS One 11: e0149349, 2016.

Growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease. Machado V, Maioli G, von Bohlen Und Halbach O, Wree A, Hölzl-Wenig G, Mandl C, Unsicker K, et al. J Neurosci 29: 13640-13648, 2009.

Deficiency in growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease. Nature 334: 345-348, 1988.

Deficiency in growth differentiation factor 15, but not lactate, is elevated in patients with Parkinson's disease. Nature 334: 345-348, 1988.